Literature DB >> 19823856

Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration.

Penelope G Foulds1, Yvonne Davidson, Manjari Mishra, David J Hobson, Kirsty M Humphreys, Mark Taylor, Nancy Johnson, Sandra Weintraub, Haruhiko Akiyama, Tetsuaki Arai, Masato Hasegawa, Eileen H Bigio, Fiona E Benson, David Allsop, David M A Mann.   

Abstract

In the present study, we have correlated plasma TDP-43 levels, as measured by ELISA, with the presence of TDP-43 pathological changes in the brains of 28 patients with frontotemporal lobar degeneration (FTLD) (14 with FTLD-TDP and 14 with FTLD-tau) and 24 patients with pathologically confirmed AD (8 with, and 16 without, TDP-43 pathological changes). Western blotting revealed full-length TDP-43, including a phosphorylated form, and a phosphorylated C-terminal fragment, in all samples examined. Both ELISA and immunohistochemistry were performed using phospho-dependent and phospho-independent TDP-43 antibodies for detection of phosphorylated and total TDP-43, respectively. Over all 52 cases, plasma levels of TDP-43, and scores of brain TDP-43 pathology, determined using TDP-43 phospho-dependent antibody correlated with the equivalent measure determined using the TDP phospho-independent antibody. In FTLD, but not AD, TDP-43 plasma levels correlated significantly with the pathology score when using the TDP-43 phospho-dependent antibody, but a similar correlation was not seen in either FTLD or AD using the TDP-43 phospho-independent antibody. With the TDP-43 phospho-independent antibody, there were no significant differences in median plasma TDP-43 levels between FTLD, or AD, patients with or without TDP-43 pathology. Using TDP-43 phospho-dependent antibody, median plasma TDP-43 levels were greater in patients with, than in those without, TDP-43 pathology for FTLD patients, though not significantly so, but not for AD patients. Present assays for TDP-43 do not differentiate between FTLD, or AD, patients with or without TDP-43 pathological changes in their brains. However, the levels of phosphorylated TDP-43 in plasma do correlate with the extent of TDP-43 brain pathology in FTLD, and therefore might be a useful surrogate marker for tracking changes in TDP-43 brain pathology during the course of this disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19823856      PMCID: PMC2809136          DOI: 10.1007/s00401-009-0594-0

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  33 in total

1.  Frontotemporal dementia with ubiquitinated cytoplasmic and intranuclear inclusions.

Authors:  J Woulfe; A Kertesz; D G Munoz
Journal:  Acta Neuropathol       Date:  2001-07       Impact factor: 17.088

2.  Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration.

Authors:  Anne M Lipton; Charles L White; Eileen H Bigio
Journal:  Acta Neuropathol       Date:  2004-09-04       Impact factor: 17.088

3.  Epitope mapping of 2E2-D3, a monoclonal antibody directed against human TDP-43.

Authors:  Hai-Xin Zhang; Kunikazu Tanji; Fumiaki Mori; Koichi Wakabayashi
Journal:  Neurosci Lett       Date:  2008-02-02       Impact factor: 3.046

4.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Tetsuaki Arai; Masato Hasegawa; Haruhiko Akiyama; Kenji Ikeda; Takashi Nonaka; Hiroshi Mori; David Mann; Kuniaki Tsuchiya; Mari Yoshida; Yoshio Hashizume; Tatsuro Oda
Journal:  Biochem Biophys Res Commun       Date:  2006-10-30       Impact factor: 3.575

5.  The relationship between extramotor ubiquitin-immunoreactive neuronal inclusions and dementia in motor neuron disease.

Authors:  Ian R A Mackenzie; Howard Feldman
Journal:  Acta Neuropathol       Date:  2002-10-17       Impact factor: 17.088

6.  The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein.

Authors:  S Taniguchi; A M McDonagh; S M Pickering-Brown; Y Umeda; T Iwatsubo; M Hasegawa; D M A Mann
Journal:  Neuropathol Appl Neurobiol       Date:  2004-02       Impact factor: 8.090

7.  Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.

Authors:  Kunihiro Uryu; Hanae Nakashima-Yasuda; Mark S Forman; Linda K Kwong; Christopher M Clark; Murray Grossman; Bruce L Miller; Hans A Kretzschmar; Virginia M-Y Lee; John Q Trojanowski; Manuela Neumann
Journal:  J Neuropathol Exp Neurol       Date:  2008-06       Impact factor: 3.685

8.  Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.

Authors:  Tetsuaki Arai; Ian R A Mackenzie; Masato Hasegawa; Takashi Nonoka; Kazhuhiro Niizato; Kuniaki Tsuchiya; Shuji Iritani; Mitsumoto Onaya; Haruhiko Akiyama
Journal:  Acta Neuropathol       Date:  2009-01-13       Impact factor: 17.088

9.  Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases.

Authors:  Hanae Nakashima-Yasuda; Kunihiro Uryu; John Robinson; Sharon X Xie; Howard Hurtig; John E Duda; Steven E Arnold; Andrew Siderowf; Murray Grossman; James B Leverenz; Randy Woltjer; Oscar L Lopez; Ronald Hamilton; Debby W Tsuang; Douglas Galasko; Eliezer Masliah; Jeffrey Kaye; Christopher M Clark; Thomas J Montine; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2007-07-25       Impact factor: 17.088

10.  Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease.

Authors:  Hiroshige Fujishiro; Hirotake Uchikado; Tetsuaki Arai; Masato Hasegawa; Haruhiko Akiyama; Osamu Yokota; Kuniaki Tsuchiya; Takashi Togo; Eizo Iseki; Yoshio Hirayasu
Journal:  Acta Neuropathol       Date:  2008-11-28       Impact factor: 17.088

View more
  23 in total

Review 1.  Biomarkers to identify the pathological basis for frontotemporal lobar degeneration.

Authors:  Murray Grossman
Journal:  J Mol Neurosci       Date:  2011-07-22       Impact factor: 3.444

2.  Disposable immunoplatforms for the simultaneous determination of biomarkers for neurodegenerative disorders using poly(amidoamine) dendrimer/gold nanoparticle nanocomposite.

Authors:  Verónica Serafín; Claudia A Razzino; Maria Gamella; María Pedrero; Eloy Povedano; Ana Montero-Calle; Rodrigo Barderas; Miguel Calero; Anderson O Lobo; Paloma Yáñez-Sedeño; Susana Campuzano; José M Pingarrón
Journal:  Anal Bioanal Chem       Date:  2020-05-30       Impact factor: 4.142

Review 3.  [German consortium for frontotemporal lobar degeneration].

Authors:  M Otto; A C Ludolph; B Landwehrmeyer; H Förstl; J Diehl-Schmid; M Neumann; H A Kretzschmar; M Schroeter; J Kornhuber; A Danek
Journal:  Nervenarzt       Date:  2011-08       Impact factor: 1.214

Review 4.  On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.

Authors:  F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel
Journal:  Prog Neurobiol       Date:  2011-09-03       Impact factor: 11.685

5.  Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.

Authors:  Jeffrey M Statland; Dan Moore; Yunxia Wang; Maureen Walsh; Tahseen Mozaffar; Lauren Elman; Sharon P Nations; Hiroshi Mitsumoto; J Americo Fernandes; David Saperstein; Ghazala Hayat; Laura Herbelin; Chafic Karam; Jonathan Katz; Heather M Wilkins; Abdulbaki Agbas; Russell H Swerdlow; Regina M Santella; Mazen M Dimachkie; Richard J Barohn
Journal:  Muscle Nerve       Date:  2018-11-26       Impact factor: 3.217

6.  Biomarkers in the primary progressive aphasias.

Authors:  Murray Grossman
Journal:  Aphasiology       Date:  2014-09       Impact factor: 2.773

Review 7.  Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers.

Authors:  Alexander G Thompson; Elizabeth Gray; Sabrina M Heman-Ackah; Imre Mäger; Kevin Talbot; Samir El Andaloussi; Matthew J Wood; Martin R Turner
Journal:  Nat Rev Neurol       Date:  2016-05-13       Impact factor: 42.937

Review 8.  Behavioural variant frontotemporal dementia--defining genetic and pathological subtypes.

Authors:  Jonathan D Rohrer
Journal:  J Mol Neurosci       Date:  2011-05-11       Impact factor: 3.444

Review 9.  Biomarkers in frontotemporal lobar degeneration.

Authors:  Murray Grossman
Journal:  Curr Opin Neurol       Date:  2010-12       Impact factor: 5.710

Review 10.  TDP-43 in aging and Alzheimer's disease - a review.

Authors:  Andrea C Wilson; Brittany N Dugger; Dennis W Dickson; Deng-Shun Wang
Journal:  Int J Clin Exp Pathol       Date:  2011-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.